Keywords: Bristol-Myers Squibb, Reckitt Benckiser, OTC medicines, Latin America, Baraclude, US patent invalidated, Teva, Hepatitis B

Bristol-Myers gets $438 million under Latin America OTC deal with Reckitt Benckiser; Baraclude patent ruled invalid

Article | 13 February 2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a three-year collaboration agreement with UK-headquartered Reckitt Benckiser (LSE: RBL) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Reckitt Benckiser

Bristol-Myers Squibb

Teva Pharmaceutical Industries

Go to company listing

Related Drugs

Baraclude

Go to drug listing